186 related articles for article (PubMed ID: 16544440)
1. Pegaptanib for neovascular age-related macular degeneration.
Maberley D
Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440
[TBL] [Abstract][Full Text] [Related]
2. Pegaptanib: new drug. In macular degeneration: too many risks for too little benefit.
Prescrire Int; 2006 Aug; 15(84):127-9. PubMed ID: 16989023
[TBL] [Abstract][Full Text] [Related]
3. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
4. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
Ferrara N; Damico L; Shams N; Lowman H; Kim R
Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
[TBL] [Abstract][Full Text] [Related]
5. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
6. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Schiller DS
Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
[TBL] [Abstract][Full Text] [Related]
7. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
[TBL] [Abstract][Full Text] [Related]
8. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Takeda AL; Colquitt J; Clegg AJ; Jones J
Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
[TBL] [Abstract][Full Text] [Related]
9. Pegaptanib for neovascular age-related macular degeneration.
Gragoudas ES; Adamis AP; Cunningham ET; Feinsod M; Guyer DR;
N Engl J Med; 2004 Dec; 351(27):2805-16. PubMed ID: 15625332
[TBL] [Abstract][Full Text] [Related]
10. Pegaptanib for the treatment of age-related macular degeneration.
Zhou B; Wang B
Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
[TBL] [Abstract][Full Text] [Related]
11. Pegaptanib for wet macular degeneration.
Fraunfelder FW
Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
[TBL] [Abstract][Full Text] [Related]
12. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
Maier M; Feucht N; Huebner M; Lohmann C
Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
Nguyen QD; Shah SM; Hafiz G; Quinlan E; Sung J; Chu K; Cedarbaum JM; Campochiaro PA;
Ophthalmology; 2006 Sep; 113(9):1522.e1-1522.e14. PubMed ID: 16876249
[TBL] [Abstract][Full Text] [Related]
16. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
[TBL] [Abstract][Full Text] [Related]
17. [New drugs; pegaptanib and ranibizumab].
van Bronswijk H; Dubois EA; van Meurs JC; Cohen AF
Ned Tijdschr Geneeskd; 2008 Jan; 152(2):82-4. PubMed ID: 18265796
[TBL] [Abstract][Full Text] [Related]
18. Regulatory aspects of drug approval for macular degeneration.
Gryziewicz L
Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
Sivaprasad S; Hykin P; Saeed A; Beatty S; Grisanti S; Staurenghi G; Olea JL; Campos A; Barbosa A; Rito L; Silva R; Faria R; Eldem B; Kadayifçilar S; Kolar P; Feucht N; Maestroni L
Eye (Lond); 2010 May; 24(5):793-8. PubMed ID: 19786957
[TBL] [Abstract][Full Text] [Related]
20. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
Atmani K; Coscas F; Coscas G; Soubrane G
Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
